|
業務類別
|
Biotechnology |
|
業務概覽
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
| 公司地址
| 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502 |
| 電話號碼
| +1 650 837-7000 |
| 傳真號碼
| +1 650 837-8300 |
| 公司網頁
| https://www.exelixis.com |
| 員工數量
| 4600 |
| Dr. Dana T. Aftab, PhD |
Executive Vice President, Research and Development |
美元 619.32K |
29/08/2025 |
| Mr. Patrick J. Haley |
Executive Vice President, Commercial |
-- |
16/04/2025 |
| Mr. Jeffrey J. Hessekiel |
Executive Vice President and Secretary |
美元 654.34K |
07/11/2025 |
| Dr. Michael M. Morrissey, PhD |
Director, President and Chief Executive Officer |
美元 1.25M |
10/02/2026 |
| Mr. Christopher J. Senner |
Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 788.29K |
10/02/2026 |
| Dr. Brenda Hefti, J.D.,PhD |
General Counsel |
-- |
07/11/2025 |
|
|
| Dr. Mary C. Beckerle, PhD |
Independent Director |
10/02/2026 |
| Ms. Julie Anne Smith |
Independent Director |
10/02/2026 |
| Mr. Tomas J. Heyman |
Independent Director |
10/02/2026 |
| Dr. Maria C. Freire, PhD |
Independent Director |
10/02/2026 |
| Dr. Stelios Papadopoulos,PhD |
Chairman of the Board |
10/02/2026 |
| Dr. Michael M. Morrissey, PhD |
Director, President and Chief Executive Officer |
10/02/2026 |
| Mr. Jack L. Wyszomierski, M.S. |
Independent Director |
10/02/2026 |
| Dr. George H. Poste, D.V.M.,F.R.S.,PhD |
Independent Director |
10/02/2026 |
| Mr. Robert Oliver, M.B.A. |
Independent Director |
10/02/2026 |
| Mr. David E. Johnson |
Independent Director |
10/02/2026 |
| Dr. Sue Gail Eckhardt, M.D. |
Independent Director |
10/02/2026 |
|
|
|
|
